Nama's AI scorecard currently rates Vertex Pharmaceuticals Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is VRTX's P/E ratio?

Vertex Pharmaceuticals trades at a trailing price-to-earnings ratio of 28.8.

When does VRTX report earnings?

Vertex Pharmaceuticals's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $4.78.

What is the VRTX price target?

The median analyst price target from 28 analysts is $582.50, with a range of $350.00 – $725.00.

Is VRTX Shariah compliant?

Nama's AAOIFI-style screen reads Vertex Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Vertex Pharmaceuticals (VRTX)

Healthcare · Biotechnology · NASDAQ

S&P 500Nasdaq-100

Vertex Pharmaceuticals (VRTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $138.71B, a trailing price-to-earnings ratio of 28.8 and a free-cash-flow yield of 2.3%. Over the most recent reported fiscal year, revenue grew 8.9%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.2/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +21.5% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-3.8%

How far the last close sits under the highest price of the past five years.

Market cap	$138.71B
Trailing P/E	28.8
Price / book	6.8
Price / sales	11.0
FCF yield	2.3%
Dividend yield	—
Gross margin	86.0%
Operating margin	38.0%
Net margin	35.0%
Revenue growth (YoY)	+8.9%
Revenue growth (3-yr annual)	+10.3%
EPS growth (YoY)	+6248.3%
FCF/share growth (YoY)	—
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

VRTX earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $4.78). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$4.76	$4.78	-0.4%	$3.44B
Q2 2026	Aug 3, 2026	$4.73	$4.75	-0.4%	$3.33B
Q1 2026	May 4, 2026	$4.47	$4.31	+3.7%	$2.99B
Q4 2025	Feb 12, 2026	$5.03	$5.15	-2.3%	$3.19B

VRTX analyst price target

Median target $582.50 from 28 analysts, ranging $350.00 – $725.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live VRTX data on Nama Insights →

Recent Congressional trades

Vertex Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
David J. Taylor	House	Sell	$1,001 - $15,000	Sep 5, 2026
Thomas H Tuberville	Senate	Sell	$1,001 - $15,000	Aug 5, 2026
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
David J. Taylor	House	Sell	$1,001 - $15,000	Feb 2, 2026
Julia Letlow	House	Buy	$1,001 - $15,000	Jan 13, 2026
David J. Taylor	House	Buy	$1,001 - $15,000	Sep 2, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Jefferson Shreve	House	Sell	$15,001 - $50,000	Jun 22, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	Apr 14, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	Apr 14, 2025

VRTX FAQ

Is VRTX a buy?: Nama's AI scorecard currently rates Vertex Pharmaceuticals Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is VRTX's P/E ratio?: Vertex Pharmaceuticals trades at a trailing price-to-earnings ratio of 28.8.
When does VRTX report earnings?: Vertex Pharmaceuticals's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $4.78.
What is the VRTX price target?: The median analyst price target from 28 analysts is $582.50, with a range of $350.00 – $725.00.
Is VRTX Shariah compliant?: Nama's AAOIFI-style screen reads Vertex Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.